sildenafil citrate · Ibsa · NDA 210858
Vybrique
Earliest generic entry, as listed · earliest of 4 marketed strengths
16 Dec 2033
Blocked by patent: US 11123287.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11123287 | product | 16 Dec 2033 |
Exclusivities · 1 unexpired
| NP | new product | 16 Dec 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210858 · 001 · RLD | film, oral | EQ 25MG BASE | 16 Dec 2033 |
| 210858 · 002 · RLD | film, oral | EQ 50MG BASE | 16 Dec 2033 |
| 210858 · 003 · RLD | film, oral | EQ 75MG BASE | 16 Dec 2033 |
| 210858 · 004 · RLD | film, oral | EQ 100MG BASE | 16 Dec 2033 |